Antibody Discovery Market is expected to reach US$ 4.92 billion by 2030

Publisher: The Insight Partners

Monoclonal Antibodies Segment to Hold Significant Antibody Discovery Market Share During 2022–2030

According to our latest study on "Antibody Discovery Market Forecast to 2030 – Global Analysis – Antibody Type, Nature, Service, and End User," the market is expected to reach US$ 4.92 billion by 2030 from US$ 2.94 billion in 2022. The report emphasizes the key factors driving the market and prominent players' developments. Factors such as the increasing investments in research & development and the rising incidence of cancer propel the antibody discovery market growth. However, the high cost of production impedes the market growth.

Antibody discovery, a nuanced endeavor, is a process of discovering novel antibodies. This process involves the search for antibodies that recognize and bind to specific targets, with applications extending to diagnostics and therapy. Phage display and hybridoma technology are the widely used antibody discovery methods. Antibodies with specificity to different antigens play a crucial role in developing novel drugs, vaccines, diagnostic tools, and various therapeutic modalities, which renders the scale of antibody discovery a highly importance aspect of drug and biomedical device discovery processes. The complicated process of antibody discovery gives rise to various nature of antibodies, including humanized, human, chimeric, and murine antibodies. The advancement of custom antibodies with the use of artificial intelligence (AI) and machine learning (ML) algorithms to analyze large data sets, predict antigen–antibody interactions, and optimize antibody properties. is expected to bring new antibody discovery market trends in the coming years.

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00007411

Proliferation of Biotechnology Industry in Developing Regions to Provide Market Opportunities in Coming Years

The remarkable precision of antibodies in identifying antigens makes them invaluable tools for scientists and clinicians. In modern biotechnology, antibodies are required in numerous processes, from fundamental research to innovative medical evaluations. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles. Antibodies are also crucial in antibody-based diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public–private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of biotechnology industries in regions such as Asia Pacific, South & Central America, and the Middle East & Africa.

As per the Organization for Economic Co-operation and Development (OECD), China was a frontrunner in terms of R&D expenditure as of 2019. Heavy investments encourage the adoption of advanced technologies in the healthcare sector. Governments of countries in regions such as Asia and the Middle East & Africa offer tax incentives, cheaper land, and direct investments for encouraging biotechnology companies to expand their capacities and strengthen their capabilities. Thus, countries such as the UAE, Saudi Arabia, Oman, Muscat, Bahrain, Taiwan, Malaysia, India, China, Singapore, and Japan are among the most advantageous destinations for the biotechnology industries. Furthermore, these Asian countries are more focused on exploring the application of genomics, proteomics, and biomarkers in diagnostics and therapeutics. Therefore, the ongoing proliferation of biotechnology industries in developing regions is expected to create opportunities for the antibody discovery market in the coming years.

Antibody Discovery Market, by Antibody Type:

Based on antibody type, the antibody discovery market analysis is carried out by considering the following segments: monoclonal antibodies, polyclonal antibodies, and others. The monoclonal antibodies segment held a larger market share in 2022. The same segment is anticipated to register a higher CAGR of 6.9% during the forecast period. Monoclonal antibodies (mAbs) are designed to interact specifically with diseased cells without harming healthy cells. Cancer therapy is one of the significant application areas wherein monoclonal antibodies are used. These are widely accepted biologics and are expected to present high-value opportunities to pharmaceutical manufacturers during the forecast period. Moreover, awareness about the applications of mAb therapies is increasing notably among patients and physicians. As a result, the approval of blockbuster mAbs for the treatment of various indications is expected to favor the antibody discovery market growth during the forecast period. Several drugs such as Avastin, Herceptin, Remicade, and Rituxan have been approved by the FDA for cancer, rheumatoid arthritis, Crohn's disease, ulcerative colitis, etc.

Antibody Discovery Market, by Nature:

In terms of nature, the antibody discovery market is segmented into human and humanized, chimeric, and murine. The human and humanized segment held a larger market share in 2022, and the same segment is anticipated to register a higher CAGR during the forecast period. Human and humanized antibodies are engineered genetically by grafting complementarity-determining regions (CDRs) from a non-human antibody with the desired antigen binding specificity into the corresponding CDRs of another antibody, more prominently derived from humans. These antibodies are gaining significant acceptance and popularity because of their higher specificity and stability, and lower costs. Additionally, human and humanized antibodies have a strong track record of clinical efficacy.

Antibody Discovery Market, by Services:

By services, the market is segmented into phage display, hybridoma, transgenic animal, yeast display, and single cell. The phage display segment dominated the antibody discovery market share in 2022, and the same segment is anticipated to register a higher CAGR of 7.3% during the forecast period. Phage display is a technique used for in vitro antibody selection. Viruses that infect bacteria are mainly used as vectors of genes for the expression of antibody fragments (proteins), which are typically single-chain variable fragments (scFv) or Fab fragments present on the virus. The expressed antibody fragments can then be examined for binding to a specific target of interest. Major advantages of phage display technology include speed, simplicity, and cost-effectiveness associated with the process of identification of binders.

Antibody Discovery Market, by Geography:

The geographic scope of the antibody discovery market report includes North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). The increasing prevalence of cancer, the strong presence of antibody research organizations, and technological advancements in the R&D sector help in the market expansion in North America. An upsurge in funding further enables the development of new technologies by allowing the pooling of resources and expertise across countries and organizations, and conducting research work into existing antibody treatments. This has led to a better understanding of the immune system, and the development of effective and targeted antibodies. Additionally, the increased funding allows scientists to conduct large-scale clinical trials that are mandatory to evaluate the effectiveness of a particular antibody. The strategic presence of key players positioned in North America drives the expansion of the antibody discovery market size.

Apart from factors driving the market, the antibody discovery market report emphasizes major developments by prominent players. Creative Biolabs, Evotec, BioDuro-Sundia, Bruker Cellular Analysis, Biocytogen, Charles River Laboratories, Aragen Life Sciences Pvt. Ltd, Twist Bioscience, NanoCellect Biomedical, and Sartorius AG are among the prominent players operating in the market.

Contact Us
Contact Person: Content Team 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com